These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19615886)

  • 1. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review.
    Jassem J; Carroll C; Ward SE; Simpson E; Hind D
    Eur J Cancer; 2009 Nov; 45(16):2749-58. PubMed ID: 19615886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
    Alsaloumi L; Shawagfeh S; Abdi A; Basgut B
    Oncol Res Treat; 2020; 43(12):694-702. PubMed ID: 32950984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis.
    Jiang Z; Yang Y; Li L; Yue Z; Lan L; Pan Z
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S957-S963. PubMed ID: 30539829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
    Xu B; Sun T; Zhang Q; Zhang P; Yuan Z; Jiang Z; Wang X; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Shen K; Yu S; Li H; Tang L; Qiu R;
    Ann Oncol; 2021 Feb; 32(2):218-228. PubMed ID: 33188874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
    Jones L; Hawkins N; Westwood M; Wright K; Richardson G; Riemsma R
    Health Technol Assess; 2004 Feb; 8(5):iii, xiii-xvi, 1-143. PubMed ID: 14960257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
    Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
    J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.
    Petrelli F; Di Cosimo S; Lonati V; Barni S
    Clin Breast Cancer; 2016 Oct; 16(5):327-334. PubMed ID: 27282844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.
    Roché H; Conte P; Perez EA; Sparano JA; Xu B; Jassem J; Peck R; Kelleher T; Hortobagyi GN
    Breast Cancer Res Treat; 2011 Feb; 125(3):755-65. PubMed ID: 21128114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
    Palmieri C; Alifrangis C; Shipway D; Tat T; Watson V; Mackie D; Emson M; Coombes RC
    Oncologist; 2012; 17(11):1429-e47. PubMed ID: 23002126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
    Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.
    Barnett CM
    Pharmacotherapy; 2009 Dec; 29(12):1482-90. PubMed ID: 19947807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to maximize the efficacy of taxanes in breast cancer.
    Tubiana-Hulin M
    Cancer Treat Rev; 2005; 31 Suppl 4():S3-9. PubMed ID: 16360546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer.
    Li S; Meng W; Zhang J; Xie X; Hao C; Jia Y; Tong Z
    J Cancer Res Ther; 2020 Sep; 16(5):1069-1076. PubMed ID: 33004749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Fumoleau P; Largillier R; Clippe C; Dièras V; Orfeuvre H; Lesimple T; Culine S; Audhuy B; Serin D; Curé H; Vuillemin E; Morère JF; Montestruc F; Mouri Z; Namer M
    Eur J Cancer; 2004 Mar; 40(4):536-42. PubMed ID: 14962720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
    Mauri D; Polyzos NP; Salanti G; Pavlidis N; Ioannidis JP
    J Natl Cancer Inst; 2008 Dec; 100(24):1780-91. PubMed ID: 19066278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.